Michaela Liedtke

Publications

• A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia. Patel S, Liedtke M, Ngo D, Medeiros BC. Leuk Lymphoma. 2013
• AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Penchala SC, Connelly S, Wang Y, Park MS, Zhao L, Baranczak A, Rappley I, Vogel H, Liedtke M, Witteles RM, Powers ET, Reixach N, Chan WK, Wilson IA, Kelly JW, Graef IA, Alhamadsheh MM. Proc Natl Acad Sci U S A. 2013; 110 (24): 9992-7
• Lenalidomide, melphalan and dexamethasone in an immunoglobulin light chain amyloidosis patient population with high rates of advanced cardiac involvement. Dinner S, Witteles W, Afghahi A, Witteles R, Arai S, Lafayette R, Schrier S, Liedtke M. Haematologica. 2013
• Multiple myeloma, version 1.2013. Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar R. J Natl Compr Canc Netw. 2013; 11 (1): 11-7
• Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Pollyea DA, Zehnder J, Coutre S, Gotlib JR, Gallegos L, Abdel-Wahab O, Greenberg P, Zhang B, Liedtke M, Berube C, Levine R, Mitchell BS, Medeiros BC. Haematologica. 2013; 98 (4): 591-6
• The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. Dinner S, Witteles W, Witteles R, Lam A, Arai S, Lafayette R, George TI, Schrier SL, Liedtke M. Br J Haematol. 2013; 161 (3): 367-72
• Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. Sun D, Elson P, Liedtke M, Medeiros BC, Earl M, Alizadeh A, Bates J, Sekeres MA, Coutre S, Kalaycio M, Sobecks R, Copelan E, Advani AS. Am J Hematol. 2012; 87 (10): 957-60
• Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies. Varr BC, Liedtke M, Arai S, Lafayette RA, Schrier SL, Witteles RM. J Heart Lung Transplant. 2012; 31 (3): 325-31
• Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options. Dunn T, Cho M, Medeiros B, Logan A, Ungewickell A, Liedtke M. Hematology. 2012
• More than a frog in the throat: a case series and review of localized laryngeal amyloidosis. Stevenson R, Witteles R, Damrose E, Arai S, Lafayette RA, Schrier S, Afghahi A, Liedtke M. Arch Otolaryngol Head Neck Surg. 2012; 138 (5): 509-11
• Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Liedtke M, Twist CJ, Medeiros BC, Gotlib JR, Berube C, Bieber MM, Bhat NM, Teng NN, Coutre SE. Haematologica. 2012; 97 (1): 30-7
• Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Pollyea DA, Kohrt HE, Gallegos L, Figueroa ME, Abdel-Wahab O, Zhang B, Bhattacharya S, Zehnder J, Liedtke M, Gotlib JR, Coutre S, Berube C, Melnick A, Levine R, Mitchell BS, Medeiros BC. Leukemia. 2012; 26 (5): 893-901
• The transcription factor encyclopedia. Yusuf D, Butland SL, Swanson MI, Bolotin E, Ticoll A, Cheung WA, Zhang XY, Dickman CT, Fulton DL, Lim JS, Schnabl JM, Ramos OH, Vasseur-Cognet M, de Leeuw CN, Simpson EM, Ryffel GU, Lam EW, Kist R, Wilson MS, Marco-Ferreres R, Brosens JJ, Beccari LL, Bovolenta P, Benayoun BA, Monteiro LJ, Schwenen HD, Grontved L, Wederell E, Mandrup S, Veitia RA, Chakravarthy H, Hoodless PA, Mancarelli MM, Torbett BE, Banham AH, Reddy SP, Cullum RL, Liedtke M, Tschan MP, Vaz M, Rizzino A, Zannini M, Frietze S, Farnham PJ, Eijkelenboom A, Brown PJ, Laperrière D, Leprince D, de Cristofaro T, Prince KL, Putker M, del Peso L, Camenisch G, Wenger RH, Mikula M, Rozendaal M, Mader S, Ostrowski J, Rhodes SJ, Van Rechem C, Boulay G, Olechnowicz SW, Breslin MB, Lan MS, Nanan KK, Wegner M, Hou J, Mullen RD, Colvin SC, Noy PJ, Webb CF, Witek ME, Ferrell S, Daniel JM, Park J, Waldman SA, Peet DJ, Taggart M, Jayaraman PS, Karrich JJ, Blom B, Vesuna F, O'Geen H, Sun Y, Gronostajski RM, Woodcroft MW, Hough MR, Chen E, Europe-Finner GN, Karolczak-Bayatti M, Bailey J, Hankinson O, Raman V, LeBrun DP, Biswal S, Harvey CJ, DeBruyne JP, Hogenesch JB, Hevner RF, Héligon C, Luo XM, Blank MC, Millen KJ, Sharlin DS, Forrest D, Dahlman-Wright K, Zhao C, Mishima Y, Sinha S, Chakrabarti R, Portales-Casamar E, Sladek FM, Bradley PH, Wasserman WW. Genome Biol. 2012; 13 (3): R24
• Plasma cell leukemia: concepts and management. Liedtke M, Medeiros BC. Expert Rev Hematol. 2010; 3 (5): 543-9
• Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience. Kohrt HE, Patel S, Ho M, Owen T, Pollyea DA, Majeti R, Gotlib J, Coutre S, Liedtke M, Berube C, Alizadeh AA, Medeiros BC. Am J Hematol. 2010; 85 (11): 877-81
• Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6. Liedtke M, Ayton PM, Somervaille TC, Smith KS, Cleary ML. Blood. 2010; 116 (1): 63-70
• Therapeutic targeting of MLL. Liedtke M, Cleary ML. Blood. 2009; 113 (24): 6061-8
• Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. Kohrt H, Logan A, Temmins C, Witteles R, Liedtke M, Medeiros B. Leuk Lymphoma. 2008; 49 (3): 581-5
• Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD. Ann Oncol. 2006; 17 (6): 909-13
• Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase. Liedtke M, Pandey P, Kumar S, Kharbanda S, Kufe D. Oncogene. 1998; 17 (15): 1889-92
• A site-directed mutagenesis study to identify amino acid residues involved in the catalytic function of the restriction endonuclease EcoRV. Selent U, Rüter T, Köhler E, Liedtke M, Thielking V, Alves J, Oelgeschläger T, Wolfes H, Peters F, Pingoud A. Biochemistry. 1992; 31 (20): 4808-15